3-{7-氯-3-(3,5-二甲基苯基)-4-[2-(哌啶-2-基)乙氧基]喹啉-6-基}苯甲酰胺 | 1021911-30-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 中文名称: 3-{7-氯-3-(3,5-二甲基苯基)-4-[2-(哌啶-2-基)乙氧基]喹啉-6-基}苯甲酰胺
• 英文名称: 3-{7-chloro-3-(3,5-dimethylphenyl)-4-[2-(piperidin-2-yl)ethoxy]quinolin-6-yl}benzamide
• 英文别名: 3-(7-chloro-3-(3,5-dimethylphenyl)-4-{2-[(2R)-piperidin-2-yl]ethoxy}quinolin-6-yl)benzamide；3-[7-chloro-3-(3,5-dimethylphenyl)-4-[2-[(2R)-piperidin-2-yl]ethoxy]quinolin-6-yl]benzamide
• CAS: 1021911-30-7
• 化学式: C₃₁H₃₂ClN₃O₂
• 分子量: 514.067
• InChiKey: CYMMIRGLEOIHAR-XMMPIXPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  37
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  77.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  3-氯-4-碘苯胺 在 N-溴代丁二酰亚胺(NBS) 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 caesium carbonate 、 溶剂黄146 、 三苯基膦 、 三氟乙酸 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二苯醚 、 二氯甲烷 、 水 为溶剂， 反应 5.88h， 生成 3-{7-氯-3-(3,5-二甲基苯基)-4-[2-(哌啶-2-基)乙氧基]喹啉-6-基}苯甲酰胺
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2

  摘要：

  Agonists of somatostatin receptor subtype 2 (sst(2)) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst(2), and these were optimized to provide small molecules with sst(2) binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.

  DOI：

  10.1021/jm101501b

文献信息

• Somatostatin Agonists
  申请人：Eastman Brian

  公开号：US20090258853A1

  公开（公告）日：2009-10-15

  This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.

  本发明涉及一种能够激活生长抑素并且选择性地作用于生长抑素受体亚型SSTR2的化合物。这些化合物可用于治疗和预防糖尿病及其相关病理，包括视网膜病变、神经病变和肾病。其中许多化合物具有口服活性。因此，本发明的目的在于描述这些化合物，进一步地，描述生长抑素激动剂的特定优选立体异构体。另一个目的是描述制备这些化合物的方法和工艺。还有一个目的是描述使用这些化合物作为活性成分的方法和组合物。
• SOMATOSTATIN AGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1996196A2

  公开（公告）日：2008-12-03
• [EN] SOMATOSTATIN AGONISTS<br/>[FR] AGONISTES DE SOMATOSTATINE
  申请人：MERCK & CO INC

  公开号：WO2008051272A2

  公开（公告）日：2008-05-02

  [EN] This invention relates to compounds which are agonists of somatostatin and selective toward somatostatin receptor subtype SSTR2. The compounds are useful in the treatment and prevention of diabetes, and diabetes-related pathologies, including retinopathy, neuropathy and nephropathy. Many of the compounds are orally active. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the somatostatin agonists. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof.
  [FR] L'invention concerne des composés qui sont des agonistes de somatostatine et des récepteurs de somatostatine sélectifs de sous-type SSTR2. Les composés selon l'invention sont utiles dans le traitement et la prévention du diabète et des pathologies liées au diabète, notamment la rétinopathie, la neuropathie et la néphropathie. Bon nombre de ces composés sont oralement actifs. L'invention concerne également les stéréoisomères spécifiques préférés des ces agonistes de somatostatine. L'invention concerne encore des procédés de préparation de ces composés, ainsi que des méthodes et des compositions utilisant ces composés comme principe actif.
• Design, Synthesis, and Evaluation of Novel 3,6-Diaryl-4-aminoalkoxyquinolines as Selective Agonists of Somatostatin Receptor Subtype 2
  作者：Scott E. Wolkenberg、Zhijian Zhao、Catherine Thut、Jill W. Maxwell、Terrence P. McDonald、Fumi Kinose、Michael Reilly、Craig W. Lindsley、George D. Hartman

  DOI：10.1021/jm101501b

  日期：2011.4.14

  Agonists of somatostatin receptor subtype 2 (sst(2)) have been proposed as therapeutics for the treatment of proliferative diabetic retinopathy and exudative age-related macular degeneration. An HTS screen identified 2-quinolones as weak agonists of sst(2), and these were optimized to provide small molecules with sst(2) binding and functional potency comparable to peptide agonists. Agonist 21 was shown to inhibit rat growth hormone secretion following systemic administration and to inhibit ocular neovascular lesion formation after local administration.